https://www.selleckchem.com/pr....oducts/relacorilant.
Non-small cell lung cancer (NSCLC) patients with oncogenic ROS1 rearrangements would inevitably develop drug resistance and disease progression after receiving targeted oncogene therapy. Here, we present a metastatic lung adenocarcinoma patient harboring a CD74-ROS1 fusion who initially responded to crizotinib and then developed resistance after acquiring a rarely reported BRAF V600E mutation. The impact of epilepsy on the quality of life of the patient can be considerably high with far-reaching and life-long consequences. The goal
Mi piace
Commento
Condividi
